U.S. Biotech Stock News

Steel Dynamics (STLD) has drawn investor interest after recent trading left the shares with a mixed short term performance, including a 1 day decline and modest moves over the week and past month. See our latest analysis for Steel Dynamics. While the latest 1 day share price return of 0.87% and a flat 30 day move suggest some hesitation, the 90 day share price return of 18.66% and 1 year total shareholder return of 39.95% point to momentum that has been stronger over longer periods. The 5...

MoonLake Immunotherapeutics (NasdaqCM:MLTX) is back in focus after fresh FDA feedback allowed the company to move ahead with a Biologics License Application for Sonelokimab in hidradenitis suppurativa using existing trial data. See our latest analysis for MoonLake Immunotherapeutics. The FDA update has arrived after a volatile stretch for MoonLake, with a 30 day share price return of 25.17% and a 90 day share price return of 79.16%, even as the 1 year total shareholder return sits at a 61.74%...

If you are wondering whether Kimberly-Clark is attractively priced right now, the key question is how its current share price lines up against the value of its cash flows and assets. The stock last closed at US$99.32, with returns of 1.4% over 7 days, a 1.3% decline over 30 days, a 2.1% decline year to date, and an 18.7% decline over the past year. The 3 year and 5 year returns are 17.7% and 9.8% declines respectively. Recent news around Kimberly-Clark has focused on broader investor...

PNC Financial Services Group (PNC) closed out FY 2025 with fourth quarter revenue of US$5.9 billion and basic EPS of US$4.88. This set the tone for a year where trailing twelve month revenue reached US$22.3 billion and EPS came in at US$16.71. Over the past year, net profit margin moved to 29.7% from 26.5%, alongside trailing earnings growth of 20.4%. This frames a results season where higher profitability and a 3.05% dividend yield sit at the center of the story for investors watching how...

Marqeta, Inc. has appointed Patti Kangwankij as Chief Financial Officer, effective February 9, 2026, and its board has authorized a US$100 million share repurchase program, while recent filings also show stock sales by a director and the Chief Administrative Officer. The combination of a seasoned CFO with deep payments experience and a sizeable buyback authorization points to a sharpened focus on capital allocation and financial discipline. We’ll now examine how the new CFO appointment,...

IDT Corporation recently reported past record quarterly results, with a 4% rise in consolidated revenue and a 31% increase in earnings per share, while shareholders approved changes to its equity incentive plan and CFO Marcelo Fischer sold 7,929 Class B shares in mid‑January 2026. This combination of stronger profitability, refreshed performance‑linked compensation, and insider selling offers fresh insight into how IDT is aligning executive incentives with recent operating momentum. We’ll...

Gorilla Technology Group recently announced three project wins in Taiwan across public safety, port operations, and environmental protection, alongside a multi-year, approximately US$1.40 billion AI-ready data center partnership in Southeast Asia and an investment in Astrikos.ai to strengthen its AI infrastructure offerings. Together with record Q3 2025 results, 2026 revenue guidance of US$137–$200 million, and a growing project pipeline, these developments highlight Gorilla’s push to scale...

In recent weeks, Twilio has attracted heightened attention as analysts and investors reacted to positive earnings and revenue growth forecasts alongside cautious ratings, insider share sales, and rising short interest, all against a backdrop of broader tech-sector volatility earlier this month. This mix of improving earnings expectations and more skeptical sentiment offers a useful lens for understanding how market perception can disconnect from operating performance for...

If you are wondering whether iRhythm Holdings at around US$167 a share still offers value, the key question is how its current price lines up with what the business may reasonably be worth. The stock has had a mixed run, with a 6.8% decline over the last week and a 4.0% decline over the last month, but a 54.3% return over the past year and a 67.3% return over three years add important context to that picture. Recent coverage has focused on iRhythm Holdings as a listed medical device company...

LyondellBasell Industries recently reported weak earnings marked by significant one-time write-offs, raising concerns about its ability to sustain its currently high dividend payout in a difficult chemicals market. These developments have sharpened investor focus on whether the company’s cost-cutting efforts and portfolio reshaping can offset prolonged industry headwinds and protect shareholder returns. Against this backdrop of weak earnings and dividend uncertainty, we will assess how the...

If you are wondering whether Guidewire Software at about US$158.99 is starting to look interesting or still feels expensive, this article walks through what the current share price could mean for you as an investor. The stock has pulled back recently, with a 14.1% decline over the last 7 days, a 20.5% decline over the last 30 days, a 15.3% decline year to date, and an 11.0% decline over the past year. Over longer periods, the 3 year return sits at 127.2% and the 5 year return at 28.5%. These...

In recent months, National Health Investors completed US$89.2 million of healthcare investments, including a US$52.1 million purchase of a 107‑unit assisted living and memory care community in Jamison, Pennsylvania, while reporting Q3 2025 earnings per share that came in above analyst expectations despite revenue falling short. This combination of accretive senior housing expansion and better‑than‑expected profitability has reinforced perceptions of operational resilience in a challenging...

If you are wondering whether MDU Resources Group is fairly priced or not at around US$20.66, you are in the right place to size up what the market might be baking into this stock. The share price has returned 2.0% over the last week, 7.8% over the last month, 4.0% year to date, 15.8% over the last year, 97.0% over 3 years and 126.3% over 5 years, which gives plenty of context for anyone thinking about the balance of risk and reward today. Recent moves in the stock come against a backdrop of...

Deere (DE) is heading into its upcoming earnings release with several pressure points in focus, including more than 2,000 layoffs at U.S. factories, recent EPS underperformance versus Wall Street, and a projected US$1.2b tariff hit. See our latest analysis for Deere. At a share price of US$514.40, Deere has seen a 7 day share price return of 5.39% and a 90 day share price return of 11.24%. The 5 year total shareholder return of 79.93% points to a stronger long run record, even as recent...

Fresh coverage of PagSeguro Digital (PAGS) is drawing attention to the stock, as investors weigh its current valuation, capital return plans, and the earnings sensitivity to potential Brazilian interest rate cuts that are expected in early 2026. See our latest analysis for PagSeguro Digital. At a share price of $10.08, PagSeguro Digital has delivered a 30 day share price return of 5.44% and a 90 day share price return of 11.63%, while the 1 year total shareholder return of 56.58% contrasts...

Northern Oil and Gas recently drew investor attention with commentary highlighting its roughly 8% dividend yield, expanding production from over 11,000 wells, and negative free cash flow driven by rapid growth amid weaker energy prices. This combination of high income, a diversified non-operating asset base, and questions over dividend sustainability has sharpened the focus on how resilient the company’s cash generation really is. We’ll now examine how concerns about negative free cash flow...

Event overview and why it matters for Marcus & Millichap (MMI) IPA Capital Markets, a division of Marcus & Millichap (MMI), arranged US$93.5 million in construction financing for the office to residential conversion of 830 Third Avenue in Manhattan. The deal spotlights the firm’s role in large urban redevelopment projects. See our latest analysis for Marcus & Millichap. Against this backdrop, Marcus & Millichap’s recent office to residential financing news comes after a mixed share price...

CAVA Group (CAVA) is back in focus after a cluster of upbeat analyst opinions, fresh institutional buying, a new Chief Operations Officer, and the company’s largest menu launch yet all converged to reset expectations. See our latest analysis for CAVA Group. The latest menu launch, leadership change and fresh analyst coverage have arrived alongside a 30 day share price return of 26.7% and a year to date share price return of 19.1%. This comes even as the 1 year total shareholder return sits at...

Earlier this month, ZIM Integrated Shipping Services approved the election of Ron Hadassi and Ran Gritzerstein to its Board of Directors at the January 2, 2026 AGM, while investors were informed that the company is in advanced stages of a strategic review assessing multiple acquisition proposals. These board changes, combined with an ongoing review of potential buyers, highlight how ZIM’s governance and ownership structure could materially influence its future direction and capital...

If you are wondering whether Medline is offering fair value at its current price, this article walks you through what the numbers are saying and what that could mean for you. Medline shares recently closed at US$44.12, with returns of 8.9% over the last 7 days, 5.9% over the last 30 days, and 8.6% year to date, which has put the stock on more investors' radar. Recent company updates and sector commentary around medical suppliers have given investors more information to work with, which can...

Ambarella (AMBA) has drawn fresh attention after CES, where it introduced the CV7 edge AI vision chip and the Ambarella Developer Zone, moves aimed at supporting faster rollouts of edge AI applications. See our latest analysis for Ambarella. Those CES launches come after a choppy stretch for the stock, with a 1 day share price return of 6.39% contrasting with a 30 day return of 5.23% and a 1 year total shareholder return of 14.93%. This suggests that long term momentum has been weak even as...

Compañía de Minas BuenaventuraA (BVN) has drawn fresh attention after a strong past 3 months, with the share price showing a 35.20% total return and a 22.33% move over the past month. See our latest analysis for Compañía de Minas BuenaventuraA. That recent momentum sits on top of a much longer run, with a 1 year total shareholder return of 175.85% and a 3 year total shareholder return above 3x, while the current share price is US$34.68 after a small 1 day pullback. If this kind of move has...

Viridian Therapeutics recently announced that the FDA has accepted its Biologics License Application for thyroid eye disease drug veligrotug, granting Priority Review with a target decision date of June 30, 2026, while the company also progresses a European filing and pivotal phase 3 trials for elegrobart (VRDN-003). This cluster of regulatory milestones meaningfully advances Viridian’s thyroid eye disease franchise, concentrating attention on how its pipeline could reshape treatment options...

Disc Medicine (IRON) is back in focus after the FDA extended its review of the company’s experimental therapy bitopertin, citing questions around trial data integrity and potential abuse risk. See our latest analysis for Disc Medicine. Those FDA questions and the recent executive hire have played out against a softer tape, with the 7 day share price return of 9.23% and 90 day share price return of 18.63% contrasting with a 1 year total shareholder return of 21.78% and a very large 3 year...